Recently, the National Center for Clinical Laboratories (NCCL) published the results of the 2019 International External Quality Assessment of Circulating Tumor DNA (ctDNA) Gene Mutation Detection, Jiaxing ACCB Diagnostics Ltd. (hereinafter referred to as Jiaxing ACCB), a wholly-owned subsidiary of Beijing ACCB Biotech Ltd., participated in and successfully passed this quality assessment!
Purpose and significance of ctDNA detection
ctDNA is an important complementary diagnostic technique in clinical practice. It has a high clinical application and assessment value in the fields of early tumor screening, tumor targeted therapy and drug resistance monitoring. It also has such advantages as non-invasive/minimally invasive, simple and repeatable detection, and dynamic tracking of cancer-related information. At present, it has been widely used in the diagnosis and treatment of common tumors such as non-small-cell lung cancer, breast cancer and colorectal cancer, and has been recommended by many domestic and foreign guides. The content of circulating tumor DNA (ctDNA) is very low in the blood, accounting for about 1% of the total cell-free DNA, and its content is even only 0.1% or lower in the early or intermediate stage of tumor or early stage of recurrence, so the detection of low-frequency mutation is of particular significance, and the requirements for sensitivity and specificity of the detection technology is also very demanding.
We take detection seriously each time
Since its inception, Jiaxing ACCB has continuously optimized and improved the comprehensive technical platform construction in the field of full-cycle tumor companion diagnosis, enriched the detection application scenes, and expanded the technical precision and application range of detection, especially in the field of next-generation sequencing. In this field, from the introduction of detection equipment, high-standard establishment of the laboratory, and standardized implementation of detection processes and quality control system to the high-quality building of the bioinformatics analysis team, software and hardware have been combined, and joint efforts have been made to guarantee companion diagnostics through precise detection! A slight deviation in detection results may give birth to totally different outcomes for the diagnosis and treatment. Precise detection is not only the basis of precise diagnosis, but also the footstone of precise treatment. We adhere to the detection precision each time and ensure the quality of each sample. We do not pursue the number of successes, but 100% success rate instead!
In the future, ACCB will continue to maintain high-standard and high-quality detection, provide more professional and accurate detection services for patients, and contribute to the development of precision medicine in